Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20016570HPVENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS20015209HPVENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS20017537HPVENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS20019599HPVENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS20019600HPVENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS20030706HPVENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS44006907HTLV-1ENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TVIS44041211HTLV-1ENSG00000135090.14protein_codingTAOK3NoNo51347G3V1Q8
Q9H2K8
TCGA Plot Options
Drug Information
GeneTAOK3
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009393
UniProt IDQ9H2K8
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830